Cargando…
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated treatment effects vary by site of...
Autores principales: | Merlino, Dante J., Johnson, Jennifer M., Tuluc, Madalina, Gargano, Stacey, Stapp, Robert, Harshyne, Larry, Leiby, Benjamin E., Flanders, Adam, Zinner, Ralph, Axelrod, Rita, Curry, Joseph, Cognetti, David M., Mannion, Kyle, Kim, Young J., Rodeck, Ulrich, Argiris, Athanassios, Luginbuhl, Adam J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738605/ https://www.ncbi.nlm.nih.gov/pubmed/33344227 http://dx.doi.org/10.3389/fonc.2020.566315 |
Ejemplares similares
-
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
por: Luginbuhl, Adam J., et al.
Publicado: (2022) -
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
por: Johnson, Jennifer M, et al.
Publicado: (2023) -
Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes
por: Topf, Michael C., et al.
Publicado: (2017) -
Metformin Clinical Trial in HPV+ and HPV– Head and Neck Squamous Cell Carcinoma: Impact on Cancer Cell Apoptosis and Immune Infiltrate
por: Curry, Joseph M., et al.
Publicado: (2018) -
Prognostic Significance of Tumor-Associated Macrophage Content in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kumar, Ayan Tyagi, et al.
Publicado: (2019)